INTERVIEW: USA - ANTITRUST - PHARMACEUTICAL IN-HOUSE COUNSEL

Marc Brotman (Pfizer): U.S. and global antitrust issues from a pharmaceutical in-house counsel perspective

Interview conducted by Kent Bernard, Fordham School of Law and Anna Pavlik, Institute of Competition Law.

What is your background? I’ve had a focus on antitrust work since starting at Weil Gotshal, with my first large matter being the predatory pricing case that Northwest and Continental Airlines brought against our client American Airlines. I also worked on a trade secret case for Quaker Oats during my tenure there and a number of merger analyses and reviews by the FTC and DOJ. Since coming to Pfizer, in addition to my antitrust work, I’ve provided legal counsel on some of Pfizer’s largest and highest profile medicines and currently support Pfizer’s Corporate Affairs division. While my pre-Pfizer experience was U.S. focused, my work here has required me to counsel on a global basis and interact with regulators across numerous jurisdictions. Over your fourteen years of career at Pfizer,

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Pfizer (New York)
  • Fordham University
  • United First Partners (New York)

Quotation

Marc Brotman, Kent Bernard, Anna M. Pavlik, Marc Brotman (Pfizer): U.S. and global antitrust issues from a pharmaceutical in-house counsel perspective, February 2014, Concurrences N° 1-2014, Art. N° 62205, pp. 7-9

Visites 715

All reviews